New Delhi: Transformation and adaptation of digital know-how have instilled vital adjustments in the healthcare section, particularly in the diagnostic sector. From labs being outfitted with synthetic intelligence (AI) and the Internet of Things (IoT), fluorescence immunoassay in in-vitro diagnostics (IVD), point-of-care (POC) testing, robotic course of automation, rising at-home diagnostic options, predictive genetic exams, and data-driven lab optimisation options to next-gen digital instruments, the diagnostics spectrum has developed on three key imperatives – inclusion, innovation, and influence.To decode India’s diagnostic worth chain, and the way stakeholders are paving India’s diagnostic journey of the future, ETHealthworld is again with the second version of India Diagnostics Summit 2023 (IDS 2023) themed ‘In Quest of Futuristic Diagnostics’ in affiliation with Empe Diagnostics, supporting companions Transasia, Shimadzu, Biogenix, Skye Air, and Thermo Fisher Scientific, teaching associate Rathee, and affiliation associate Admi.
Dr Sonia Trikha, DGHS, Government of Haryana will likely be the visitor of honour for IDS 2023, Dr Trikha will share insights on ‘Easing Public-Private Partnership in Diagnostics through Evolving’, adopted by panel discussions and associate shows.
Panel Discussions:
The summit will host influential leaders from the diagnostics sector who will share their insights on some pertinent points like the speedy diagnostic package market, the significance of accreditations for personal giants, investments in the diagnostic sector, the rising threats of infectious ailments, improvements and the future of good labs.
Following the visitor of honour’s deal with, Dr Sushil Shah, Chairman, Metropolis Healthcare Ltd will ship the keynote deal with on the ‘Impact of digital pathology corporations on the diagnostic trade’ and the ‘Pros and cons of venturing into worldwide markets for diagnostic corporations’.
The inaugural panel dialogue (PD) will likely be on ‘Benchmarking: Quality, Cost & Regulation in Dx Spectrum’. The session will see the participation of CK Mishra, Former Union Secretary, MoHFW and Environment, Forests and Climate Change, Government of India, Dr Renu Swarup, Former Secretary, Department of Biotechnology, Ministry of Science & Technology, Government of India, Dr Harsh Mahajan, Founder & Chief Radiologist, Mahajan Imaging & Labs, and Dr Avinash Phadke, President & Mentor, Agilus Diagnostics Ltd. The inaugural panel will likely be moderated by Dr Anuradha Jain, Advisor Health Systems Strengthening, USAID.
Sharing her insights on attending the summit, Dr Swarup, stated, “It is essential as we can not meet the market wants until we deal with all three. Quality and regulation are so intrinsically linked and it’s crucial that whereas we deal with these we hold our deal with the value. Affordable and accessible modern merchandise are the want for nationwide and world markets. We have seen throughout COVID how we produced a big quantity of diagnostics to fulfill the nation’s requirement of COVID testing and all three components had been emphasised. Our diagnostics met all worldwide high quality norms, went by rigorous regulatory scrutiny, and had been reasonably priced at scale for testing a big inhabitants throughout the nation. Today we’ve got a really well-established analysis and innovation ecosystem which permits diagnostics to be developed whereas preserving all these components in thoughts.”
Voicing his ideas on the components that can drive the development of the diagnostics trade, Dr Phadke added, “With respect to high quality, there’s a want for minimal requirements to make sure that good high quality care is delivered to sufferers. The development of the trade relies on a number of components together with an ageing inhabitants, rising incidence of each non-communicable ailments and power circumstances, higher insurance coverage penetration, and the demand for superior diagnostic instruments. The trade has grown with the assist of good high quality providers, whereas additionally creating jobs and including worth to the complete healthcare ecosystem.”
The inaugural PD will likely be adopted by a session on ‘The significance of standardisation and operational uniformity of path labs.’ Dr Ajay Phadke, Director, Strategy & Business Development, Agilus Diagnostics Ltd will average the dialogue. The panellists embody Dr Okay Madangopal, Advisor, Public Health Administration NHSRC, MoHFW, Government of India, Ram Ray, Chief Growth Officer, Mylab Discovery Solutions, and Dr Leena Appicatlaa, Head, Lab Operations, HCG Triesta Sciences.
Post the dialogue on ‘The significance of standardisation and operational uniformity of path labs’, a associate presentation on ‘Transforming Conventional Clinical Diagnostics Solutions: Befitting Emerging’ by Dr Manoj Chugh, Vice President, R&D (Reagents), Transasia Bio-Medicals Ltd will observe.
The associate presentation will likely be succeeded by a management speak on ‘Investments in Diagnostics – Still the Easiest Bet?’. The session will likely be moderated by Dr Arjun Dang, CEO, Dr Dang’s Lab. The panellists for the dialogue will likely be Anand Okay, Chief Executive Officer, Agilus Diagnostics Ltd, Aravind Viswanathan, CEO, Transasia BioMedicals Ltd, Dr Mansi Aggarwal, Partner, Alkemi Growth Capital, and Raghavendra Goud, Global CEO, Empe Diagnostics.
Elucidating his ideas on investments in the Indian diagnostics market, Anand Okay stated, “The Indian diagnostics market is increasing. We consider the sector has the potential to generate appreciable worth over the close to future by partnerships and consolidation. There are many nuances in the diagnostics trade. While it’s simple to make an entry into the trade, there are a number of challenges to maintain and develop. Top organised chains are better off resulting from testing capabilities, networks, and expertise in delivering superior buyer providers. The rising prevalence of non-communicable ailments (NCDs) and power circumstances, an ageing inhabitants, rising consciousness of well being, and a mindset shift amongst customers are some of the development drivers of the trade. Besides these, insurance coverage penetration, a choice for evidence-based remedy, and rising per capita earnings can even propel the trade ahead.”
The management speak on ‘Investments in Diagnostics – Still the Easiest Bet?’ will likely be succeeded by a dialogue on ‘Growing Threats of Infectious Disease – Dx Industry Coping up?’. Dr Kamini Walia, Senior Scientist, ICMR will average the session. The panellists for the dialogue embody Dr Vivek Nangia, Principal Director & Head, Department of Pulmonology, and Respiratory Medicine, Max Super Speciality Hospitals, Vikas Manchanda, Professor, Maulana Azad Medical College, and Dr Chand Wattal, Chairman & Hony Senior Consultant, Institute of Clinical Microbiology & Immunology, GRIPMER.
The subsequent PD will likely be adopted by a associate presentation by Raghavendra Goud Vaggu, Global CEO, Empe Diagnostics., which will likely be adopted by one other associate presentation by Bhaumik H Trivedi, Assistant Manager Business Development- Diagnostics, Shimadzu.
This will likely be succeeded by a associate presentation by Santosh Kumar Srivastava, CEO & MD, Biogenix. ThermoFisher will additional stage one other associate presentation.
Moving forward Dr Nilesh Shah, President & Chief of Science & Innovation, Metropolis Healthcare Ltd will average a PD on ‘Innovation and Future of Smart Labs: Aspirations and Actions: Automating Inventory Management in the Lab.’ Dr Ravi Gaur, Founder, DRG Path Labs, Varsha Vadera, Head, Laboratory Medicine & Advanced Diagnostics, Kokilaben Dhirubhai Ambani Hospital, Dr Reena Nakra, Principal Director (Lab Management & Technical Excellence), Dr Lal PathLabs, and Dr Aarti Khanna, Head Haematology, Pathkind Labs will likely be collaborating in the dialogue.
Considering the present situation round good labs, Dr Shah shared, “Smart labs are going to be inevitable in the future. I’m positive there’s going to be standardisation, minimal necessities for every of the labs will likely be anticipated from the authorities. I’m additionally anticipating some norms however not with out automation. Smart labs have two parts-automation, and biotechnology, and each will collectively convey anticipated high quality and quantity scale when all compliances are put collectively. Without this, will probably be tough for the good labs to outlive or keep in the race or stay compliant as per the necessities.”
After the dialogue on ‘Innovation and Future of Smart Labs: Aspirations and Actions: Automating Inventory Management in the Lab’, a associate presentation will likely be staged by Ankit Kumar, CEO, Skye Air Mobility on ‘Applications of Drones in the Current Healthcare Industry’. This session will likely be adopted by a training associate presentation by Arundhati Goverkar, Founder, Rathee on ‘Where do ‘we’ slot in factoring the human parts in tech-led development in Dx’.
The valedictory deal with will likely be succeeded by Narendra Singh, Programme Manager, Ayushman Bharat Digital Health Mission, who will likely be sharing his insights on the benefits of Ayushman Bharat Digital Health Mission (ABDM) for pathologists and LMIS suppliers. Lastly, the closing deal with will likely be given by Rashmi Mabiyan Kaur, Principal Correspondent, ETHealthworld.
The India Diagnostics Summit 2023 will conclude with ETHealthworld acknowledging the efforts of diagnostic stakeholders who’re serving to the trade’s transformation with their modern and transformational developments.
